Annexin Pharmaceuticals AB (publ) (STO: ANNX)
Sweden
· Delayed Price · Currency is SEK 0.554
+0.004 (0.73%)
Aug 30, 2024, 5:24 PM CET
ANNX Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 61.72 | 56.19 | 43.94 | 33.16 | 26.24 | 25.75 | Upgrade
|
| Other Revenue | 0.86 | 0.17 | 0.65 | 0.45 | 0.07 | 0.12 | Upgrade
|
| Revenue | 62.59 | 56.35 | 44.59 | 33.6 | 26.31 | 25.87 | Upgrade
|
| Revenue Growth (YoY) | 26.77% | 26.38% | 32.69% | 27.73% | 1.69% | 16.81% | Upgrade
|
| Cost of Revenue | 43.27 | 41.51 | 40.74 | 37.07 | 35.37 | 27.87 | Upgrade
|
| Gross Profit | 19.31 | 14.84 | 3.85 | -3.46 | -9.06 | -2 | Upgrade
|
| Selling, General & Admin | 15.72 | 15.72 | 15.82 | 15.59 | 11.69 | 12.33 | Upgrade
|
| Other Operating Expenses | 0.54 | - | - | 0.03 | 1.27 | -0.47 | Upgrade
|
| Operating Expenses | 22.51 | 21.55 | 20.74 | 19.78 | 16.19 | 14.77 | Upgrade
|
| Operating Income | -3.19 | -6.71 | -16.89 | -23.24 | -25.25 | -16.77 | Upgrade
|
| Interest Expense | -0 | - | -0.13 | -0.08 | -0.22 | -0.1 | Upgrade
|
| Interest & Investment Income | 0.36 | 0.36 | - | - | - | 0.03 | Upgrade
|
| Earnings From Equity Investments | -0.1 | -0.1 | -0.04 | - | - | 2.05 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | -0 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -2.94 | -6.45 | -17.06 | -23.32 | -25.47 | -14.79 | Upgrade
|
| Pretax Income | -2.94 | -6.45 | -17.06 | -23.32 | -25.47 | -14.79 | Upgrade
|
| Earnings From Continuing Operations | -2.94 | -6.45 | -17.06 | -23.32 | -25.47 | -14.79 | Upgrade
|
| Net Income | -2.94 | -6.45 | -17.06 | -23.32 | -25.47 | -14.79 | Upgrade
|
| Net Income to Common | -2.94 | -6.45 | -17.06 | -23.32 | -25.47 | -14.79 | Upgrade
|
| Shares Outstanding (Basic) | 39 | 39 | 35 | 28 | 24 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 40 | 35 | 28 | 24 | 23 | Upgrade
|
| Shares Change (YoY) | -0.33% | 16.59% | 24.51% | 14.21% | 5.00% | 31.77% | Upgrade
|
| EPS (Basic) | -0.08 | -0.16 | -0.49 | -0.84 | -1.05 | -0.64 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.16 | -0.49 | -0.84 | -1.05 | -0.64 | Upgrade
|
| Free Cash Flow | 8.23 | -0.01 | -10.5 | -15 | -22.54 | -12.4 | Upgrade
|
| Free Cash Flow Per Share | 0.21 | -0.00 | -0.30 | -0.54 | -0.93 | -0.53 | Upgrade
|
| Gross Margin | 30.86% | 26.33% | 8.64% | -10.31% | -34.44% | -7.72% | Upgrade
|
| Operating Margin | -5.10% | -11.90% | -37.88% | -69.16% | -95.98% | -64.81% | Upgrade
|
| Profit Margin | -4.70% | -11.45% | -38.25% | -69.40% | -96.82% | -57.15% | Upgrade
|
| Free Cash Flow Margin | 13.15% | -0.02% | -23.54% | -44.64% | -85.69% | -47.92% | Upgrade
|
| EBITDA | -2.39 | -6.32 | -16.51 | -22.85 | -25.08 | -16.54 | Upgrade
|
| EBITDA Margin | -3.82% | -11.22% | -37.02% | -68.00% | -95.32% | -63.95% | Upgrade
|
| D&A For EBITDA | 0.8 | 0.39 | 0.39 | 0.39 | 0.18 | 0.22 | Upgrade
|
| EBIT | -3.19 | -6.71 | -16.89 | -23.24 | -25.25 | -16.77 | Upgrade
|
| EBIT Margin | -5.10% | -11.90% | -37.88% | -69.16% | -95.98% | -64.81% | Upgrade
|
| Revenue as Reported | 62.59 | 56.35 | 44.59 | 33.6 | 26.31 | 25.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.